Zevra Therapeutics, Inc. (ZVRA)
Nasdaq · Healthcare · Biotechnology
$10.70+7.11%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $635M
- P/E (trailing)
- 11.6
- Forward P/E
- 9.9
- 52-week range
- $8.01 – $15.04
- 52-week change
- −1.96%
- EPS (trailing)
- $0.92
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $106M (+350.91%)
- Net income
- $83.2M
- Operating margin
- −59.1%
- Diluted EPS
- $1.35
- Free cash flow
- −$2.4M
From the company’s annual report on SEC EDGAR.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.
Headquarters: Boston, United States · 61 employees · zevra.com